PROTOCOL REVIEW AND MONITORING SYSTEM (PRMS) A single Protocol Review and Monitoring System (PRMS) governs all oncology clinical trial protocols across the Consortium partner institutions and assures that cancer-relevant human research is (1) scientifically important and statistically sound; (2) designed appropriately without excluding special populations for non- scientific reason; (3) feasible, with reasonably attainable accrual targets given the available patient population; and (4) supportive of the research mission of the Consortium. The central feature of the PRMS is the Scientific Review Committee (SRC). The PRMS committee structure is responsible for approving protocols that meet its stringent and well-defined criteria. A Research Group Review is required prior to submission to the SRC as part of a two-stage review process and assures that Consortium protocols are of high scientific merit and feasible prior to investing additional institutional resources in development. The SRC evaluates scientific merit, feasibility, prioritization, and progress of all Consortium clinical trial protocols. As part of the Consortium?s trial activation process, SRC approval is required prior to IRB review. Efficient operations and weekly SRC meetings have resulted in a median overall process time of 14 calendar days (10 business days) which has remained consistent since 2015. The PRMS further ensures that during accrual, the scientific rationale for the protocol has remained relevant and that accrual is sufficient to meet the scientific aims of the trial. Since implementation of the updated Low Accrual Policy in FY 2015, the number of reviews and closures increased from 25 trials reviewed and three closures, to 74 reviewed and 24 closed in FY 2018. All protocols approved by PRMS have access to CCSG-supported centralized resources, including Clinical Protocol and Data Management (CPDM) and the Biostatistics Shared Resource (BSR). PRMS has the ultimate authority to close trials that do not demonstrate scientific progress.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-46
Application #
10125982
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-01
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Georges, George E; Doney, Kris; Storb, Rainer (2018) Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv 2:2020-2028
Duggan, Catherine; Tapsoba, Jean de Dieu; Stanczyk, Frank et al. (2018) Long-term weight loss maintenance, sex steroid hormones, and sex hormone-binding globulin. Menopause :
Yu, Ming; Maden, Sean K; Stachler, Matthew et al. (2018) Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut :
Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167
Fowler, Kyle R; Hyppa, Randy W; Cromie, Gareth A et al. (2018) Physical basis for long-distance communication along meiotic chromosomes. Proc Natl Acad Sci U S A 115:E9333-E9342
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Jeong, Kyoung Sook; Zhou, Jin; Griffin, Stephanie C et al. (2018) MicroRNA Changes in Firefighters. J Occup Environ Med 60:469-474
Appelbaum, Jacob; Wells, David; Hiatt, Joseph B et al. (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6:82
Blair, Kris M; Mears, Kevin S; Taylor, Jennifer A et al. (2018) The Helicobacter pylori cell shape promoting protein Csd5 interacts with the cell wall, MurF, and the bacterial cytoskeleton. Mol Microbiol 110:114-127
Talarico, Sarah; Korson, Andrew S; Leverich, Christina K et al. (2018) High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. Helicobacter 23:e12472

Showing the most recent 10 out of 1267 publications